A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors

Model scores of the 29,894 trials active now.

Model score 15% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 5% of the time (4,470 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2025-11-26. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: first dosedose ofcellof studytransplant
  Phrases that lowered it: patients witheffectaminotransferasesolidtumors
• Phase: 1 (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Has a data monitoring committee: not given (lowers risk) · Design
• Sponsor's past termination rate: 10% (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 123 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 18.7% (lowers risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Sponsor's past trials: 1200 (raises risk) · Sponsor's track record
• Number of arms: 5 (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports before start: 80490 (lowers risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 11471 (lowers risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 91.8% (raises risk) · Drug's FDA history
• Responsible party: sponsor (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors NCT01158274 · started 2010 · scored riskier than 40% of active trials completed
• A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors NCT02650713 · started 2016 · scored riskier than 24% of active trials completed
• A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C) NCT02627274 · started 2015 · scored riskier than 24% of active trials completed
• Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors NCT01218620 · started 2010 · scored riskier than 55% of active trials completed
• A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer NCT03292172 · started 2017 · scored riskier than 18% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.